Key points from article :
Genesis Therapeutics, a biotech spinout from Stanford University, has partnered with Genentech, a Roche subsidiary, to use artificial intelligence (AI) in drug discovery. The collaboration aims to identify new treatments for severe diseases using Genesis’ Dynamic PotentialNet AI platform and advanced neural network algorithms. While financial details remain undisclosed, the deal includes upfront payments, milestone payments, and royalties on successful therapies.
Genesis’ AI-driven approach analyses drug-target interactions to uncover new therapeutic possibilities beyond conventional methods. The company previously secured $4.1 million in seed funding to expand its AI research and development team. Genentech, known for its innovative treatments, sees AI as a way to accelerate the discovery of next-generation medicines.
This partnership follows a broader trend of pharmaceutical companies embracing AI. Genentech has recently teamed up with Vaccibody to develop personalized cancer treatments, while its parent company Roche has struck a $1.8 billion AI-powered gene therapy deal with Dyno Therapeutics.
